A new study published in NEJM Evidence validates a predictive AI biomarker for androgen deprivation therapy (ADT) benefit in prostate cancer. The study found that personalized use of short-term ADT could improve patient outcomes in men with predominantly intermediate-risk prostate cancer.
SourceUniversity Hospitals Cleveland Medical Center·JournalNEJM Evidence·TypeData/statistical analysis·DateJun 30, 2023
A new AI model has been developed to help doctors determine the extent of cancer within the prostate gland, improving the effectiveness of focal therapy. The model was found to be more accurate than magnetic resonance imaging (MRI) in predicting tumor margins, reducing the chance of cancer recurrence.
SourceUniversity of California - Los Angeles Health Sciences·JournalEuropean Urology Open Science·DateJun 27, 2023
Apple iPhone 17 Pro
Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.
Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.
A study found that monitoring early-response biomarkers enables personalized dosing in prostate cancer treatment, improving patient outcomes. The approach allowed patients to take
SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJun 26, 2023
A new prostate cancer treatment combining enzalutamide and talazoparib has been approved by the FDA, offering improved patient outcomes. The treatment was found to decrease the risk of cancer progression by 55% in a phase 3 trial.
SourceHuntsman Cancer Institute·JournalThe Lancet·DateJun 22, 2023
A randomized phase II study found that adding metformin to androgen deprivation therapy did not reduce the risk of metabolic syndrome or improve PSA response in patients with advanced prostate cancer. Metformin showed some antitumor effects through mTOR inhibition, but these were not significant.
SourceImpact Journals LLC·JournalOncotarget·TypeRandomized controlled/clinical trial·DateJun 20, 2023
The study found no improvement in freedom from progression rates for patients receiving combined EBRT and brachytherapy (COMBO) compared to those receiving brachytherapy alone (BT). Late adverse events were significantly increased in the COMBO arm, favoring BT as a standard of care for intermediate-risk prostate cancer patients.
SourceNRG Oncology·JournalJournal of Clinical Oncology·DateJun 15, 2023
Kestrel 3000 Pocket Weather Meter
Kestrel 3000 Pocket Weather Meter measures wind, temperature, and humidity in real time for site assessments, aviation checks, and safety briefings.
A new study found significant reductions in breast, colorectal and prostate cancers as well as melanoma diagnoses in Alberta during the COVID-19 pandemic. Diagnoses dropped by 43% for melanoma, 36% for colorectal and prostate, and 33% for breast cancer during the 'state of emergency' phase.
SourceCanadian Medical Association Journal·JournalCanadian Medical Association Journal·DateJun 12, 2023
A study has identified a potential treatment target for prostate cancer that is resistant to hormone therapy, a protein modification involving TRAF4. The researchers found that TRAF4 promotes the spread of cancer and may be associated with a new treatment option for patients.
SourceUniversity of Houston·JournalProceedings of the National Academy of Sciences·DateJun 12, 2023
Research in mice suggests that prostate cancer cells adapt to testosterone-deprivation therapy by producing cholesterol and generating their own testosterone. Treating aggressive tumors with inhibitors slows tumor growth. The study also points to a possible drug combination and sheds light on racial disparities in prostate cancer.
SourceWashU Medicine·JournalNature Communications·DateJun 9, 2023
A research team has identified a previously unknown weak spot in prostate cancer cells that could lead to new therapeutic approaches for other types of cancer. The study found that inhibiting this process can reduce cancer growth without affecting normal cell growth.
SourceUniversity of Connecticut·JournalMolecular Cell·TypeExperimental study·DateJun 8, 2023
A recent study found that American Indian and Alaska Native men are significantly less likely to receive prostate-specific antigen (PSA) testing and digital rectal exams from primary care providers compared to White men. This disparity results in poorer prostate cancer outcomes, particularly for men between 50-59 years old.
SourceAtrium Health Wake Forest Baptist·JournalCancer Causes & Control·DateJun 5, 2023
Meta Quest 3 512GB
Meta Quest 3 512GB enables immersive mission planning, terrain rehearsal, and interactive STEM demos with high-resolution mixed-reality experiences.
A large genome-wide association study identified novel PSA-associated variants and developed a polygenic score to correct for genetic variations in PSA levels. This approach improved biopsy referral decisions, reducing unnecessary procedures while detecting more aggressive tumors.
SourceUniversity of California San Francisco Medical Center·JournalNature Medicine·TypeObservational study·DateJun 1, 2023
The SWOG Cancer Research Network will present 30 abstracts at the ASCO 2023 annual meeting, highlighting primary results from trials S1011, S1826, S1714, and S1929. Additionally, analysis from the S1609 DART trial will be shared publicly during the meeting.
SourceSWOG Cancer Research Network·TypeRandomized controlled/clinical trial·DateMay 31, 2023
A large-scale retrospective analysis by Sylvester Comprehensive Cancer Center researchers found that differences in care, rather than genetics, likely explain disparities in advanced prostate cancer between men of African and European ancestries. Men of African ancestry are less likely to receive comprehensive genetic profiling and tar...
SourcePublic Relations Pacific LLC·JournalThe Lancet Digital Health·DateMay 24, 2023
SAMSUNG T9 Portable SSD 2TB
SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.
Researchers tracked immune cell clusters in the aging mouse prostate using highly multiplexed immune profiling. Early adulthood sees myeloid cells, while between 6-12 months old, there's a profound shift to T and B lymphocyte-dominance. The study reveals new insight into prostatic inflammaging and the window for interventions.
SourceImpact Journals LLC·JournalAging-US·TypeComputational simulation/modeling·DateMay 23, 2023
Researchers from the UCLA Jonsson Comprehensive Cancer Center are presenting findings on combination therapies for breast cancer and a potential new treatment for patients with recurrent glioma. A phase 3 study evaluating vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation is also be...
SourceUniversity of California - Los Angeles Health Sciences·DateMay 22, 2023
Experts warn that shared decision-making policies for prostate cancer testing lead to high rates of unnecessary testing and harm, particularly in older men and those from disadvantaged areas. A comprehensive risk-based approach or restricting testing to symptomatic cases could reduce overdiagnosis and overtreatment.
SourceBMJ Group·JournalThe BMJ·TypeData/statistical analysis·DateMay 17, 2023
Research suggests weight gain between ages 17-29 increases aggressive prostate cancer risk by 13% and fatal prostate cancer risk by 27%. Preventing weight gain in young adulthood may reduce prostate cancer risk. The study analyzed data from over 250,000 Swedish men, finding a significant association between weight gain and prostate can...
SourceEuropean Association for the Study of Obesity·DateMay 16, 2023
Overweight and obesity in early adulthood are associated with increased risks of colorectal cancer and non-colorectal gastrointestinal cancers. The study highlights the need for further exploration into the mechanisms driving these associations.
SourceJAMA Network·JournalJAMA Network Open·DateMay 10, 2023
DJI Air 3 (RC-N2)
DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.
A new study found a strong link between bone biomarkers and survival rates in men with hormone-sensitive prostate cancer treated with hormone therapy. The research, published in European Urology, analyzed results from a large clinical trial and found that elevated bone biomarkers were associated with an increased risk of death.
SourceUniversity of California - Davis Health·JournalEuropean Urology·DateMay 9, 2023
Moffitt researchers develop CAR T cells that target prostate cancer biomarker PSCA, killing cancer cells and preserving bone health. Zoledronate treatment enhances antitumor activity with minimal toxicity.
SourceH. Lee Moffitt Cancer Center & Research Institute·JournalScience Advances·TypeExperimental study·DateMay 3, 2023
A case series study found prostate cancer occurs in transgender women, contrary to previous reports suggesting rarity. Rates were lower than anticipated based on prior male veteran prostate cancer incidence estimates.
Apple MacBook Pro 14-inch (M4 Pro)
Apple MacBook Pro 14-inch (M4 Pro) powers local ML workloads, large datasets, and multi-display analysis for field and lab teams.
A first-of-its-kind study has estimated that transgender women taking estrogen are at a higher risk for prostate cancer, with 14 cases per 10,000 people. The study found disparities in diagnosis rates among different racial groups.
SourceUniversity of California - San Francisco·JournalJournal of the American Medical Association·DateApr 29, 2023
The study found that dose-escalated radiotherapy with short-term androgen deprivation therapy improved rates of biochemical failure, distant metastases, and prostate cancer-specific mortality. However, the trial did not meet its primary endpoint of improving overall survival for men with intermediate-risk prostate cancer.
SourceNRG Oncology·JournalJournal of Clinical Oncology·DateApr 27, 2023
A recent study published in Journal of Clinical Oncology found that dose-escalated radiotherapy with short-term androgen deprivation therapy showed no significant impact on urinary or bowel quality of life for men with intermediate-risk prostate cancer. However, the treatment did significantly decrease hormone and sexual quality of lif...
SourceNRG Oncology·JournalJournal of Clinical Oncology·DateApr 27, 2023
Fluke 87V Industrial Digital Multimeter
Fluke 87V Industrial Digital Multimeter is a trusted meter for precise measurements during instrument integration, repairs, and field diagnostics.
A new PSMA PET scoring system, the tumor-to-salivary gland ratio (PSG score), can predict patient response to <sup> 177 </sup> Lu-PSMA therapy. Patients with high PSG scores had longer PSA progression-free survival and overall survival rates.
SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateApr 20, 2023
A study of 15,296 men found that a healthy Mediterranean or Prudent diet had no impact on prostate cancer risk, while an unhealthy Western diet may increase the risk of aggressive tumors. The findings suggest avoiding Western-style diet products and adopting Mediterranean diet habits could help prevent aggressive prostate cancer.
A study published in Cancer Research Communications found that vitamin D receptor genetic differences in African American men may make them more vulnerable to prostate cancer. The researchers suggest that revised nutritional guidelines for vitamin D intake may be necessary to address these disparities.
SourceCedars-Sinai Medical Center·JournalCancer Research Communications·DateApr 18, 2023
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C)
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C) keeps Macs, tablets, and meters powered during extended observing runs and remote surveys.
A new study reveals that the HOXB13 protein regulates PSMA expression, even when the androgen receptor is absent, and identifies amino acids that are upregulated in low-PSMA tumors. This complex system of PSMA control has multiple subtypes, suggesting optimally targeted therapies.
SourceDana-Farber Cancer Institute·JournalNature Cancer·DateApr 10, 2023
Enoblituzumab, a monoclonal antibody, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body. The drug targets B7-H3 protein overexpressed on prostate cancer cells, blocking immune system inhibition and triggering tumor cell destruction by activating immune cells.
SourceJohns Hopkins Medicine·JournalNature Medicine·DateApr 6, 2023
A recent study identified novel genes that influence PARP inhibitor response in prostate cancer, including MMS22L and RNASEH2B. The research found that loss of CHEK2, a previously approved biomarker, confers resistance to PARP inhibition, highlighting the need for comprehensive genomic analysis to improve treatment decisions.
SourceBrigham and Women's Hospital·JournalNature Communications·TypeExperimental study·DateApr 4, 2023
A study published in JAMA Internal Medicine found that more US prostate cancer patients are choosing active surveillance, a preferred treatment option for low-risk cancers. The study also highlights disparities by race, ethnicity, income, and rurality in receiving active surveillance.
SourceVanderbilt University Medical Center·JournalJAMA Internal Medicine·DateApr 3, 2023
A rapid genetic testing model identified pathogenic variants in 51 patients with advanced prostate cancer, leading to discussions of possible treatment changes for 22 patients. The streamlined approach detected actionable gene variants eligible for newer targeted therapies in nearly half of patients with these variants.
SourceWolters Kluwer Health·JournalThe Journal of Urology·DateMar 29, 2023
Aranet4 Home CO2 Monitor
Aranet4 Home CO2 Monitor tracks ventilation quality in labs, classrooms, and conference rooms with long battery life and clear e-ink readouts.
A new finger-prick test for Trichomonas vaginalis has been developed by Washington State University researcher John Alderete. The test detects an antibody specific to the organism and provides rapid, affordable results, making it a potential game-changer in the fight against this prevalent but neglected STI.
SourceWashington State University·JournalPathogens·DateMar 27, 2023
ENZAMET, a new drug combination, has shown significant improvement in survival rates for men with advanced prostate cancer. After five years, the treatment led to a 67% survival rate, compared to 57% for standard therapy.
SourceUniversity of Adelaide·JournalThe Lancet Oncology·TypeRandomized controlled/clinical trial·DateMar 27, 2023
Current radiotherapy contouring guidelines often miss lesions in the prostate bed, leading to unnecessary tissue irradiation. PSMA PET mapping reveals that nearly a third of patients experience disease progression within 10 years after radical prostatectomy.
SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateMar 24, 2023
A new study from McGill University reveals that every day Canadians are exposed to Bisphenol S (BPS) in fresh foods due to chemical migration from packaging materials. High concentrations of BPS were found on thermal food labels, exceeding the European Union's regulatory limit.
SourceMcGill University·JournalEnvironmental Science & Technology·TypeExperimental study·DateMar 16, 2023
The ProtecT trial found that active monitoring of prostate cancer has the same high survival rates after 15 years as radiotherapy or surgery. Men on active monitoring were more likely to see their cancer progress, but this didn't reduce their likelihood of survival.
SourceEuropean Association of Urology·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateMar 11, 2023
Sky-Watcher EQ6-R Pro Equatorial Mount
Sky-Watcher EQ6-R Pro Equatorial Mount provides precise tracking capacity for deep-sky imaging rigs during long astrophotography sessions.
A new technique involving a small flap in the peritoneum can reduce postoperative complications in prostate cancer surgery by allowing lymphatic fluid to escape and be absorbed. The study found that this technique significantly reduced the incidence of lymphocele, a common complication where lymphatic fluid collects in the pelvis.
A recent study published in JNCCN found that the lack of genomic research for people with African ancestry is hindering efforts to reduce disparities in prostate cancer outcomes. The researchers evaluated molecular genetic results for 113 Black South African men diagnosed with advanced prostate cancer, identifying 17 pathogenic and pot...
SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateMar 10, 2023
A trial using PSMA-PET/CT scans has shown that clinicians changed their treatment plans for patients with clinically significant prostate cancer in 19% of cases, helping to detect more cancers. The technique was found to be beneficial in high-risk patients but also led to false positives requiring further investigations.
A Mediterranean diet rich in colourful fruits and vegetables helps prevent prostate cancer and speeds up recovery after radiation treatment. Foods such as tomatoes, melons, and nuts are particularly beneficial due to their high levels of lycopene and selenium.
SourceUniversity of South Australia·JournalCancers·TypeCase study·DateMar 8, 2023
A new study suggests that digital rectal examination (DRE) is not a reliable screening tool for early prostate cancer detection. Researchers found that DRE missed many cancers in their early stages, with only 3 out of 57 suspicious cases detected. This method was compared to PSA testing, which detected four times more prostate cancers.
Apple AirPods Pro (2nd Generation, USB-C)
Apple AirPods Pro (2nd Generation, USB-C) provide clear calls and strong noise reduction for interviews, conferences, and noisy field environments.
Researchers have identified mitochondrial signaling pathways as critical organelles that promote tumorigenesis and metastasis. In particular, the integrated stress response is found to engage with mitochondria to drive tumor growth, highlighting a new paradigm for understanding aggressive prostate cancer progression.
SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateMar 8, 2023
A study published in Environmental Health Perspectives found that long-term exposure to nitrate in drinking water may increase the risk of prostate cancer, especially among younger men and those with aggressive tumors. Eating a diet rich in fiber, fruits, and vegetables can help mitigate this effect.
SourceBarcelona Institute for Global Health (ISGlobal)·JournalEnvironmental Health Perspectives·TypeRandomized controlled/clinical trial·DateMar 8, 2023
The HALP score, a novel immune-nutritional marker, has been linked to prognostic ability in different cancer types. It integrates indicators of immune status and nutritional status, showing promise as a cost-effective biomarker.
SourceImpact Journals LLC·JournalOncotarget·TypeLiterature review·DateMar 6, 2023
AmScope B120C-5M Compound Microscope
AmScope B120C-5M Compound Microscope supports teaching labs and QA checks with LED illumination, mechanical stage, and included 5MP camera.
Researchers found that patients receiving salvage radiation therapy (sRT) with PSA levels above 0.25 ng/mL had a 50% higher risk of death compared to those with lower PSA levels. The study suggests delaying sRT until PSA levels exceed 0.30 ng/mL may increase mortality risk.
SourceBrigham and Women's Hospital·JournalJournal of Clinical Oncology·TypeObservational study·DateMar 6, 2023
Lung cancer death rates are projected to decrease overall in the EU and UK in 2023, however, a concerning trend is observed among women in France, Italy, and Spain. Meanwhile, pancreatic cancer death rates are forecasted to rise among women due to continued smoking habits.
SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·TypeObservational study·DateMar 5, 2023
A recent study has identified nine new genetic variants that increase the risk of prostate cancer in men of African descent, including a variant linked to aggressive forms. The findings can be used to refine polygenic risk scores and identify high-risk patients for earlier screenings.
SourceKeck School of Medicine of USC·JournalEuropean Urology·TypeMeta-analysis·DateMar 3, 2023
Researchers from Northwestern University discuss the multifaceted tumorigenic functions of EZH2, including its role in regulating translation and coactivating transcription. This new understanding may provide novel insights into advancing EZH2-targeting strategies for prostate cancer patients.
SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateMar 3, 2023
CalDigit TS4 Thunderbolt 4 Dock
CalDigit TS4 Thunderbolt 4 Dock simplifies serious desks with 18 ports for high-speed storage, monitors, and instruments across Mac and PC setups.
Researchers discovered a new personalized immunotherapy combination that treats aggressive forms of advanced prostate cancer. By blocking PD-1-expressing macrophages and Wnt/β-catenin pathway activation, the therapy significantly improves response rates in PTEN-deficient cancers.
SourceUniversity of Chicago Medical Center·JournalClinical Cancer Research·TypeExperimental study·DateMar 2, 2023
Active surveillance for managing low-risk prostate cancer is increasing nationally, but wide variation persists across practices and practitioners. The study highlights the need for continued progress to minimize overtreatment and improve the benefit-to-harm ratio of national efforts.
SourceJAMA Network·JournalJAMA Network Open·DateMar 2, 2023
Researchers analyzed zika virus effects on tumor cells and healthy cells, discovering its potential to treat prostate cancer but also triggering a persistent inflammatory process that damages the male reproductive system. The study's findings suggest long-term treatment could lead to recurrence of prostate cancer.
SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalJournal of Proteome Research·DateMar 1, 2023
A new mathematical model has been developed to optimize treatment for prostate cancer, showing promising results in eliminating cancer cells. The model explores different therapeutic strategies, including single drugs and drug combinations, and suggests that alternating therapies could significantly improve cancer treatment.
SourceUniversity of Portsmouth·JournalMathematical Biosciences·TypeComputational simulation/modeling·DateMar 1, 2023
A new AR system using HoloLens enables doctors to perform transperineal prostate interventions with high accuracy and flexibility. The system provides a 3D immersive experience, allowing doctors to guide needles to their target with ease.
SourceSPIE--International Society for Optics and Photonics·JournalJournal of Medical Imaging·DateMar 1, 2023
Celestron NexStar 8SE Computerized Telescope
Celestron NexStar 8SE Computerized Telescope combines portable Schmidt-Cassegrain optics with GoTo pointing for outreach nights and field campaigns.
A new machine learning model combines fusion gene profiling, serum PSA level, and Gleason score to predict prostate cancer recurrence with improved accuracy. The model outperformed clinical data alone and provided valuable insights into the mechanism of disease progression.
SourceElsevier·JournalAmerican Journal Of Pathology·TypeComputational simulation/modeling·DateFeb 14, 2023
Men with non-metastatic castration-resistant prostate cancer treated with enzalutamide experienced sharp reductions in PSA levels, leading to improved survival rates. A 50% decrease in PSA was associated with lower risk of metastases and longer survival time.
SourceWolters Kluwer Health·JournalThe Journal of Urology·DateFeb 10, 2023
Researchers at the University of East Anglia have developed a new blood test to detect prostate cancer with 94% accuracy. The Prostate Screening EpiSwitch (PSE) blood test significantly enhances overall detection accuracy for at-risk men, offering a rapid and minimally invasive diagnosis.
SourceUniversity of East Anglia·JournalCancer·TypeExperimental study·DateFeb 7, 2023
Scientists at Sanford Burnham Prebys have discovered a new treatment approach that can kill prostate cancer cells by targeting the PI5P4Kα enzyme. This finding has significant implications for addressing treatment resistance in prostate cancer and may lead to improved treatments for other cancers.
SourceSanford Burnham Prebys·JournalScience Advances·DateFeb 3, 2023